Identification  ||| S:0 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
miR‑130b  ||| S:18 E:27 ||| CD
as  ||| S:27 E:30 ||| IN
an  ||| S:30 E:33 ||| DT
oncogene  ||| S:33 E:42 ||| NN
in  ||| S:42 E:45 ||| IN
renal  ||| S:45 E:51 ||| FW
cell  ||| S:51 E:56 ||| FW
carcinoma  ||| S:56 E:66 ||| FW
Renal  ||| S:66 E:72 ||| FW
cell  ||| S:72 E:77 ||| FW
carcinoma  ||| S:77 E:87 ||| FW
( ||| S:87 E:88 ||| -LRB-
RCC ||| S:88 E:91 ||| NNP
)  ||| S:91 E:93 ||| -RRB-
is  ||| S:93 E:96 ||| VBZ
the  ||| S:96 E:100 ||| DT
most  ||| S:100 E:105 ||| RBS
common  ||| S:105 E:112 ||| JJ
type  ||| S:112 E:117 ||| NN
of  ||| S:117 E:120 ||| IN
renal  ||| S:120 E:126 ||| JJ
tumor ||| S:126 E:131 ||| NN
,  ||| S:131 E:133 ||| ,
which  ||| S:133 E:139 ||| WDT
has  ||| S:139 E:143 ||| VBZ
a  ||| S:143 E:145 ||| DT
poor  ||| S:145 E:150 ||| JJ
prognosis ||| S:150 E:159 ||| NN
.  ||| S:159 E:161 ||| .
Improvements  ||| S:161 E:174 ||| NNS
in  ||| S:174 E:177 ||| IN
understanding  ||| S:177 E:191 ||| VBG
the  ||| S:191 E:195 ||| DT
underlying  ||| S:195 E:206 ||| JJ
molecular  ||| S:206 E:216 ||| JJ
biology  ||| S:216 E:224 ||| NN
of  ||| S:224 E:227 ||| IN
RCC  ||| S:227 E:231 ||| NNP
has  ||| S:231 E:235 ||| VBZ
led  ||| S:235 E:239 ||| VBN
to  ||| S:239 E:242 ||| TO
systemic  ||| S:242 E:251 ||| JJ
treatments ||| S:251 E:261 ||| NNS
,  ||| S:261 E:263 ||| ,
which  ||| S:263 E:269 ||| WDT
have  ||| S:269 E:274 ||| VBP
markedly  ||| S:274 E:283 ||| RB
improved  ||| S:283 E:292 ||| VBN
patient  ||| S:292 E:300 ||| JJ
outcomes ||| S:300 E:308 ||| NNS
.  ||| S:308 E:310 ||| .
Therefore ||| S:310 E:319 ||| RB
,  ||| S:319 E:321 ||| ,
it  ||| S:321 E:324 ||| PRP
is  ||| S:324 E:327 ||| VBZ
necessary  ||| S:327 E:337 ||| JJ
and  ||| S:337 E:341 ||| CC
worthwhile  ||| S:341 E:352 ||| JJ
to  ||| S:352 E:355 ||| TO
identify  ||| S:355 E:364 ||| VB
novel  ||| S:364 E:370 ||| JJ
biomarkers  ||| S:370 E:381 ||| NN
for  ||| S:381 E:385 ||| IN
RCC ||| S:385 E:388 ||| NNP
.  ||| S:388 E:390 ||| .
MicroRNAs  ||| S:390 E:400 ||| NNP
( ||| S:400 E:401 ||| -LRB-
miRNAs ||| S:401 E:407 ||| NNP
)  ||| S:407 E:409 ||| -RRB-
have  ||| S:409 E:414 ||| VBP
been  ||| S:414 E:419 ||| VBN
found  ||| S:419 E:425 ||| VBN
to  ||| S:425 E:428 ||| TO
be  ||| S:428 E:431 ||| VB
important  ||| S:431 E:441 ||| JJ
in  ||| S:441 E:444 ||| IN
a  ||| S:444 E:446 ||| DT
wide  ||| S:446 E:451 ||| JJ
range  ||| S:451 E:457 ||| NN
of  ||| S:457 E:460 ||| IN
biological  ||| S:460 E:471 ||| JJ
and  ||| S:471 E:475 ||| CC
pathological  ||| S:475 E:488 ||| JJ
processes ||| S:488 E:497 ||| NNS
,  ||| S:497 E:499 ||| ,
including  ||| S:499 E:509 ||| VBG
cell  ||| S:509 E:514 ||| NN
differentiation ||| S:514 E:529 ||| NN
,  ||| S:529 E:531 ||| ,
migration ||| S:531 E:540 ||| NN
,  ||| S:540 E:542 ||| ,
growth ||| S:542 E:548 ||| NN
,  ||| S:548 E:550 ||| ,
proliferation ||| S:550 E:563 ||| NN
,  ||| S:563 E:565 ||| ,
apoptosis  ||| S:565 E:575 ||| NN
and  ||| S:575 E:579 ||| CC
metabolism ||| S:579 E:589 ||| NN
.  ||| S:589 E:591 ||| .
Aberrant  ||| S:591 E:600 ||| JJ
expression  ||| S:600 E:611 ||| NN
of  ||| S:611 E:614 ||| IN
miRNA‑130b  ||| S:614 E:625 ||| NNP
has  ||| S:625 E:629 ||| VBZ
previously  ||| S:629 E:640 ||| RB
been  ||| S:640 E:645 ||| VBN
reported  ||| S:645 E:654 ||| VBN
in  ||| S:654 E:657 ||| IN
tumors ||| S:657 E:663 ||| NNS
,  ||| S:663 E:665 ||| ,
however ||| S:665 E:672 ||| RB
,  ||| S:672 E:674 ||| ,
its  ||| S:674 E:678 ||| PRP$
role  ||| S:678 E:683 ||| NN
in  ||| S:683 E:686 ||| IN
RCC  ||| S:686 E:690 ||| NNP
remains  ||| S:690 E:698 ||| VBZ
to  ||| S:698 E:701 ||| TO
be  ||| S:701 E:704 ||| VB
elucidated ||| S:704 E:714 ||| NNS
.  ||| S:714 E:716 ||| .
In  ||| S:716 E:719 ||| IN
the  ||| S:719 E:723 ||| DT
present  ||| S:723 E:731 ||| JJ
study ||| S:731 E:736 ||| NN
,  ||| S:736 E:738 ||| ,
the  ||| S:738 E:742 ||| DT
upregulation  ||| S:742 E:755 ||| NN
of  ||| S:755 E:758 ||| IN
miR‑130b  ||| S:758 E:767 ||| NNP
was  ||| S:767 E:771 ||| VBD
observed  ||| S:771 E:780 ||| VBN
in  ||| S:780 E:783 ||| IN
RCC  ||| S:783 E:787 ||| NNP
tissues  ||| S:787 E:795 ||| NNS
and  ||| S:795 E:799 ||| CC
cell  ||| S:799 E:804 ||| NN
lines  ||| S:804 E:810 ||| NNS
using  ||| S:810 E:816 ||| VBG
reverse  ||| S:816 E:824 ||| JJ
transcription‑quantitative  ||| S:824 E:851 ||| CD
polymerase  ||| S:851 E:862 ||| JJ
chain  ||| S:862 E:868 ||| NN
reaction  ||| S:868 E:877 ||| NN
analysis ||| S:877 E:885 ||| NN
,  ||| S:885 E:887 ||| ,
which  ||| S:887 E:893 ||| WDT
was  ||| S:893 E:897 ||| VBD
consistent  ||| S:897 E:908 ||| JJ
with  ||| S:908 E:913 ||| IN
previous  ||| S:913 E:922 ||| JJ
microRNA  ||| S:922 E:931 ||| JJ
profiling  ||| S:931 E:941 ||| NN
in  ||| S:941 E:944 ||| IN
RCC ||| S:944 E:947 ||| NNP
.  ||| S:947 E:949 ||| .
Furthermore ||| S:949 E:960 ||| RB
,  ||| S:960 E:962 ||| ,
the  ||| S:962 E:966 ||| DT
effects  ||| S:966 E:974 ||| NNS
of  ||| S:974 E:977 ||| IN
miR‑130b  ||| S:977 E:986 ||| CD
on  ||| S:986 E:989 ||| IN
cell  ||| S:989 E:994 ||| NN
migration ||| S:994 E:1003 ||| NN
,  ||| S:1003 E:1005 ||| ,
proliferation  ||| S:1005 E:1019 ||| NN
and  ||| S:1019 E:1023 ||| CC
apoptosis  ||| S:1023 E:1033 ||| NNS
were  ||| S:1033 E:1038 ||| VBD
examined  ||| S:1038 E:1047 ||| VBN
using  ||| S:1047 E:1053 ||| VBG
a  ||| S:1053 E:1055 ||| DT
wound  ||| S:1055 E:1061 ||| JJ
scratch  ||| S:1061 E:1069 ||| NN
assay ||| S:1069 E:1074 ||| NN
,  ||| S:1074 E:1076 ||| ,
an  ||| S:1076 E:1079 ||| DT
MTT  ||| S:1079 E:1083 ||| NNP
assay  ||| S:1083 E:1089 ||| NN
and  ||| S:1089 E:1093 ||| CC
flow  ||| S:1093 E:1098 ||| NN
cytometric  ||| S:1098 E:1109 ||| NN
analysis ||| S:1109 E:1117 ||| NN
,  ||| S:1117 E:1119 ||| ,
respectively ||| S:1119 E:1131 ||| RB
.  ||| S:1131 E:1133 ||| .
The  ||| S:1133 E:1137 ||| DT
results  ||| S:1137 E:1145 ||| NNS
demonstrated  ||| S:1145 E:1158 ||| VBN
that  ||| S:1158 E:1163 ||| IN
the  ||| S:1163 E:1167 ||| DT
downregulation  ||| S:1167 E:1182 ||| NN
of  ||| S:1182 E:1185 ||| IN
miR‑130b  ||| S:1185 E:1194 ||| CD
by  ||| S:1194 E:1197 ||| IN
a  ||| S:1197 E:1199 ||| DT
synthesized  ||| S:1199 E:1211 ||| FW
inhibitor  ||| S:1211 E:1221 ||| FW
inhibited  ||| S:1221 E:1231 ||| FW
cell  ||| S:1231 E:1236 ||| FW
migration ||| S:1236 E:1245 ||| FW
,  ||| S:1245 E:1247 ||| ,
suppressed  ||| S:1247 E:1258 ||| JJ
cell  ||| S:1258 E:1263 ||| NN
proliferation  ||| S:1263 E:1277 ||| NN
and  ||| S:1277 E:1281 ||| CC
induced  ||| S:1281 E:1289 ||| JJ
RCC  ||| S:1289 E:1293 ||| NNP
cell  ||| S:1293 E:1298 ||| NN
apoptosis ||| S:1298 E:1307 ||| NN
.  ||| S:1307 E:1309 ||| .
The  ||| S:1309 E:1313 ||| DT
present  ||| S:1313 E:1321 ||| JJ
study  ||| S:1321 E:1327 ||| NN
was  ||| S:1327 E:1331 ||| VBD
the  ||| S:1331 E:1335 ||| DT
first ||| S:1335 E:1340 ||| JJ
,  ||| S:1340 E:1342 ||| ,
to  ||| S:1342 E:1345 ||| TO
the  ||| S:1345 E:1349 ||| DT
best  ||| S:1349 E:1354 ||| JJS
of  ||| S:1354 E:1357 ||| IN
our  ||| S:1357 E:1361 ||| PRP$
knowledge ||| S:1361 E:1370 ||| NN
,  ||| S:1370 E:1372 ||| ,
to  ||| S:1372 E:1375 ||| TO
suggest  ||| S:1375 E:1383 ||| VB
that  ||| S:1383 E:1388 ||| IN
miR‑130b  ||| S:1388 E:1397 ||| NNP
may  ||| S:1397 E:1401 ||| MD
be  ||| S:1401 E:1404 ||| VB
a  ||| S:1404 E:1406 ||| DT
promising  ||| S:1406 E:1416 ||| JJ
biomarker  ||| S:1416 E:1426 ||| NN
for  ||| S:1426 E:1430 ||| IN
diagnosis  ||| S:1430 E:1440 ||| NN
and  ||| S:1440 E:1444 ||| CC
a  ||| S:1444 E:1446 ||| DT
therapeutic  ||| S:1446 E:1458 ||| JJ
target  ||| S:1458 E:1465 ||| NN
for  ||| S:1465 E:1469 ||| IN
the  ||| S:1469 E:1473 ||| DT
treatment  ||| S:1473 E:1483 ||| NN
of  ||| S:1483 E:1486 ||| IN
RCC ||| S:1486 E:1489 ||| NNP
.  ||| S:1489 E:1491 ||| .
Further  ||| S:1491 E:1499 ||| JJ
investigations  ||| S:1499 E:1514 ||| NNS
are  ||| S:1514 E:1518 ||| VBP
required  ||| S:1518 E:1527 ||| VBN
to  ||| S:1527 E:1530 ||| TO
examine  ||| S:1530 E:1538 ||| VB
the  ||| S:1538 E:1542 ||| DT
roles  ||| S:1542 E:1548 ||| NNS
and  ||| S:1548 E:1552 ||| CC
target  ||| S:1552 E:1559 ||| NN
genes  ||| S:1559 E:1565 ||| NNS
of  ||| S:1565 E:1568 ||| IN
miR‑130b  ||| S:1568 E:1577 ||| CD
in  ||| S:1577 E:1580 ||| IN
RCC ||| S:1580 E:1583 ||| NNP
.  ||| S:1583 E:1585 ||| .
